



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:)	Art Unit: 1652
)	
FRIDKIN et al)	Examiner: R. Hutson
)	
Appln. No. 09/117,380)	Washington, D.C.
)	
Filed: January 27, 1999)	November 21, 2001
)	
For: ANTI-INFLAMMATORY PEPTIDES)	Atty.Docket: FRIDKIN=1
DERIVED FROM C-REACTIVE)	
PROTEIN)	

21/C
H.G.J
11/28/01
(NE)

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED
NOV 26 2001
TECH CENTER 1600/2900

In response to the Office Action dated August 21,
2001, please amend the present application as follows:

IN THE CLAIMS

Please amend claim 1 (amended) in twice-amended form
as follows:


1 (Twice-amended). An isolated peptide capable of
inhibiting *in vitro* the enzymatic activity of human Leukocyte
Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide
being selected from:

(i) a core peptide identical to positions 89-96 of
the sequence of human C-reactive protein (CRP) of the formula:

Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (of SEQ ID NO:3)

or a modification thereof characterized by:

C'



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: FRIDKIN et al
Application No.: 09/117,380

Filed: January 27, 1999

For: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN

Art Unit: 1652

Examiner: R. Hu

Washington, D.C.

Atty.'s Docket: FRIDKIN=1

Date: November 21, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment []

in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 11	MINUS	** 20		0
INDEP.	* 1	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY

RATE		ADDITIONAL FEE
x	9	\$
x	42	\$
+	140	\$
ADDITIONAL FEE TOTAL		\$

OR

OTHER THAN SMALL ENTITY

RATE		ADDITIONAL FEE	
x	18	\$	
x	84	\$	
+	280	\$	
TOTAL		\$	

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Less fees (\$) already paid for ___ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.


[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.

[] A check in the amount of \$_____ is attached (check no.).


[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197



RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 252
NOV 26 2001
TECH CENTER 1600/2900
Corres. and Mail
BOX AF